What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

European Commission President Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences. Luellen shared the company's ambitious mission ...

President Donald Trump's proposed 2026 federal budget envisages sweeping cuts to funding for Department of Health and Human Services (HHS) agencies – including the NIH – that will be a ...

Just a few months after announcing a plan to separate its drug and cell therapy businesses into two separate companies, ...

The difference comes from the sourcing of raw materials and the functioning – and even nature – of supply chains. Because the ...